Vor Biopharma (VOR) Accumulated Expenses (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Accumulated Expenses of $2.2 million for Q1 2026, up 21.18% year-over-year from $1.8 million in Q1 2025, and down 88.74% quarter-over-quarter from $19.8 million in Q4 2025.
Vor Biopharma (VOR) Accumulated Expenses (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Accumulated Expenses for 7 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 21.18% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 21.18% YoY), while the FY2025 annual figure was $19.8 million, up 53.3% from the prior year.
- Accumulated Expenses fell to $2.2 million in Q1 2026 per VOR's latest filing, from $19.8 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $58.1 million in Q2 2025 and bottomed at $1.6 million in Q1 2023.
- Historically, Accumulated Expenses has averaged $10.4 million across 5 years, with a median of $7.3 million in 2023.
- Annual changes were most pronounced in 2023 — Accumulated Expenses sank 82.98% — and 2025, when it jumped 658.93%.
- Vor Biopharma's Accumulated Expenses stood at $7.9 million in 2022, then surged by 37.88% to $10.9 million in 2023, then rose by 18.53% to $12.9 million in 2024, then soared by 53.3% to $19.8 million in 2025, then tumbled by 88.74% to $2.2 million in 2026.
- Business Quant data shows VOR's Accumulated Expenses at $2.2 million in Q1 2026, $19.8 million in Q4 2025, and $17.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.48 Mn |
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 19.76 Mn |
| Sep 30, 2025 | 17.70 Mn |
| Jun 30, 2025 | 58.10 Mn |
| Mar 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 12.89 Mn |
| Sep 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 7.66 Mn |
| Mar 31, 2024 | 1.91 Mn |
| Dec 31, 2023 | 10.88 Mn |
| Sep 30, 2023 | 4.27 Mn |
| Jun 30, 2023 | 7.26 Mn |
| Mar 31, 2023 | 1.58 Mn |
| Dec 31, 2022 | 7.89 Mn |
| Sep 30, 2022 | 3.21 Mn |
| Jun 30, 2022 | 6.29 Mn |
| Mar 31, 2022 | 9.26 Mn |
| Dec 31, 2021 | 4.18 Mn |
| Sep 30, 2021 | 5.68 Mn |